Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment

Cancer Biology and Therapy

Volumn 14, Issue 10, 2013, Pages 962-972

  Mukhopadhyay, Archana ^a   Tabanor, Kayann ^a   Chaguturu, Rathnam ^a,b   Aldrich, Jane V ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b SRI INTERNATIONAL   (United States)

Author keywords

c Myc; Cell signaling; Ceramide; Histone acetyl transferase; Inhibitor 2 of protein phosphatase 2A; Protein phosphatase 2A; Tumor suppressor lipid

Indexed keywords

C6 CERAMIDE; CERAMIDE; MYC PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

C-MYC; CELL SIGNALING; CERAMIDE; HISTONE ACETYL TRANSFERASE; INHIBITOR 2 OF PROTEIN PHOSPHATASE 2A; PROTEIN PHOSPHATASE 2A; TUMOR SUPPRESSOR LIPID;

ACETYLATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; EPITHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; HISTONE CHAPERONES; HISTONES; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PHOSPHOPROTEIN PHOSPHATASES; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84885210143     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25943     Document Type: Article

References (53)

1. Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012; 2012:327253; PMID:22530130; http://dx.doi. org/10.1155/2012/327253
2. Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res 2013; 19:1335-9; PMID:23300275; http://dx.doi.org/10.1158/1078-0432.CCR-12-2910
3. Michielsen D P, Braeckman JG, Denis L. Cabazitaxel for the treatment of prostate cancer. Expert Opin Pharmacother 2011; 12:977-82; PMID:21406025; http://dx.doi.org/10.1517/14656566.2011.567268
4. El-Amm J, Aragon-Ching JB. The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013; 5:25-40; PMID:23323145; http://dx.doi. org/10.1177/1758834012458137
5. Feldman BJ, Feldman D. The development of andro-gen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45; PMID:11900250; http://dx.doi. org/10.1038/35094009
6. Anazawa Y, Nakagawa H, Furihara M, Ashida S, Tamura K, Yoshioka H, Shuin T, Fujioka T, Katagiri T, Nakamura Y. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res 2005; 65:4578-86; PMID:15930275; http://dx.doi.org/10.1158/0008-5472.CAN-04-4564 (Pubitemid 40740793)
7. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2:113-6; PMID:12204531; http://dx.doi.org/10.1016/S1535-6108(02)00103-4 (Pubitemid 41039111)
8. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9:287-300; PMID:16616334; http://dx.doi. org/10.1016/j.ccr.2006.03.003
9. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 2009; 23:751-63; PMID:19028839; http://dx.doi.org/10.1096/fj.08-120550
10. Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. SET complex in serous epithelial ovarian cancer. Int J Cancer 2006; 119:2119-26; PMID:16823850; http://dx.doi. org/10.1002/ijc.22054 (Pubitemid 44423670)
11. Ginos MA, Page G P, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004; 64:55-63; PMID:14729608; http://dx.doi.org/10.1158/0008- 5472.CAN-03-2144 (Pubitemid 38114082)
12. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol 1998; 9:1873-80; PMID:9773788 (Pubitemid 28443484)
13. Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006; 66:820-7; PMID:16424014; http://dx.doi.org/10.1158/0008-5472.CAN-05-2445 (Pubitemid 43165947)
14. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8:355-68; PMID:16286244; http://dx.doi. org/10.1016/j.ccr.2005.10.015 (Pubitemid 41579831)
15. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leu-kemias. Cancer Metastasis Rev 2008; 27:159-68; PMID:18213449; http://dx.doi.org/10.1007/s10555-008-9119-x
16. Adachi Y, Pavlakis GN, Copeland TD. Identification and characterization of SET, a nuclear phosphopro-tein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem 1994; 269:2258-62; PMID:8294483 (Pubitemid 24035441)
17. Li M, Guo H, Damuni Z. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 1995; 34:1988-96; PMID:7531497; http://dx.doi.org/10.1021/ bi00006a020
18. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996; 271:11059-62; PMID:8626647; http://dx.doi.org/10.1074/jbc.271.19.11059 (Pubitemid 26155931)
19. Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol 2006; 26:2832-44; PMID:16537924; http://dx.doi. org/10.1128/MCB.26.7.2832-2844. 2006
20. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14:152-60; PMID:18329957; http://dx.doi.org/10.1016/j.molmed.2008.02.001
21. Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N, Bachs O. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem 2003; 278:1158-64; PMID:12407107; http://dx.doi. org/10.1074/jbc.M207497200 (Pubitemid 36790797)
22. Carujo S, Estanyol JM, Ejarque A, Agell N, Bachs O, Pujol MJ. Glyceraldehyde 3-phosphate dehy-drogenase is a SET-binding protein and regulates cyclin B-cdk1 activity. Oncogene 2006; 25:4033-42; PMID:16474839; http://dx.doi.org/10.1038/sj.onc.1209433 (Pubitemid 44024866)
23. Compagnone NA, Zhang P, Vigne JL, Mellon SH. Novel role for the nuclear phosphoprotein SET in transcriptional activation of P450c17 and initiation of neurosteroidogenesis. Mol Endocrinol 2000; 14:875-88; PMID:10847589; http://dx.doi.org/10.1210/me.14.6.875 (Pubitemid 32260500)
24. Nagata K, Kawase H, Handa H, Yano K, Yamasaki M, Ishimi Y, Okuda A, Kikuchi A, Matsumoto K. Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis. Proc Natl Acad Sci USA 1995; 92:4279-83; PMID:7753797; http://dx.doi.org/10.1073/pnas.92.10.4279
25. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001; 104:119-30; PMID:11163245; http://dx.doi.org/10.1016/S0092-8674(01)00196-9 (Pubitemid 32144977)
26. Gamble MJ, Erdjument-Bromage H, Tempst P, Freedman L P, Fisher R P. The histone chaperone TAF-I/SET/INHAT is required for transcription in vitro of chromatin templates. Mol Cell Biol 2005; 25:797-807; PMID:15632079; http://dx.doi.org/10.1128/MCB.25.2.797-807.2005 (Pubitemid 40096599)
27. ten Klooster J P, Leeuwen Iv, Scheres N, Anthony EC, Hordijk PL. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J 2007; 26:336-45; PMID:17245428; http://dx.doi.org/10.1038/ sj.emboj.7601518 (Pubitemid 46160935)
28. Goc A, Abdalla M, Al-Azayzih A, Somanath PR. Rac1 activation driven by 14-3-3ζ dimerization promotes prostate cancer cell-matrix interactions, motility and transendothelial migration. PLoS One 2012; 7:e40594; PMID:22808202; http://dx.doi.org/10.1371/journal. pone.0040594
29. Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 2008; 27:147-58; PMID:18246411; http://dx.doi. org/10.1007/s10555-008-9128-9
30. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003; 112:659-72; PMID:12628186; http://dx.doi.org/10.1016/S0092-8674(03)00150-8 (Pubitemid 36331778)
31. Jensen SL, Wood DP Jr., Banks ER, Veron M, Lascu I, McRoberts JW, Rangnekar VM. Increased levels of nm23 H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate. World J Urol 1996; 14(Suppl 1):S21-5; PMID:8738406; http://dx.doi.org/10.1007/BF00182060
32. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek M P. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011; 30:2504-13; PMID:21297667; http://dx.doi.org/10. 1038/onc.2010.622
33. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9:139-50; PMID:18216770; http://dx.doi.org/10.1038/nrm2329 (Pubitemid 351158911)
34. Ogretmen B. Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 2006; 580:5467-76; PMID:16970943; http://dx.doi.org/10.1016/ j.feb-slet.2006.08.052 (Pubitemid 44465911)
35. Ogretmen B, Hannun YA. Biologically active sphin-golipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604-16; PMID:15286740; http://dx.doi.org/10.1038/nrc1411 (Pubitemid 39025055)
36. Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006; 5:200-8; PMID:16505092; http://dx.doi.org/10. 1158/1535-7163.MCT-05-0420
37. Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, Viani P, Tettamanti G. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002; 39:105-13; PMID:12112362; http://dx.doi.org/10.1002/glia.10087 (Pubitemid 34817051)
38. Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann E P. Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ 2003; 10:240-8; PMID:12700652; http://dx.doi.org/10.1038/sj.cdd. 4401145 (Pubitemid 36553466)
39. Koyanagi S, Kuga M, Soeda S, Hosoda Y, Yokomatsu T, Takechi H, Akiyama T, Shibuya S, Shimeno H. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide syn-thase. Int J Cancer 2003; 105:1-6; PMID:12672022; http://dx.doi.org/10.1002/ijc.11024 (Pubitemid 36418477)
40. Rylova SN, Somova OG, Dyatlovitskaya EV. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry (Mosc) 1998; 63:1057-60; PMID:9795275 (Pubitemid 128588127)
41. Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA. C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Prostate 2003; 57:66-79; PMID:12886525; http://dx.doi.org/10.1002/pros.10275 (Pubitemid 37070151)
42. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435:1262-6; PMID:15988529; http://dx.doi. org/10.1038/nature03672 (Pubitemid 40943093)
43. Watson JA, McKenna DJ, Maxwell P, Diamond J, Arthur K, McKelvey-Martin VJ, Hamilton PW. Hyperacetylation in prostate cancer induces cell cycle aberrations, chromatin reorganization and altered gene expression profiles. J Cell Mol Med 2010; 14(6B):1668-82; PMID:19583812; http://dx.doi. org/10.1111/j.1582-4934.2009.00835.x
44. Dart DA, Brooke GN, Sita-Lumsden A, Waxman J, Bevan CL. Reducing prohibitin increases histone acety-lation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene 2012; 31:4588-98; PMID:22179832; http://dx.doi.org/10.1038/ onc.2011.591
45. Debret R, Brassart-Pasco S, Lorin J, Martoriati A, Deshorgue A, Maquart FX, Hornebeck W, Rahman I, Antonicelli F. Ceramide inhibition of MMP-2 expression and human cancer bronchial cell invasiveness involve decreased histone acetylation. Biochim Biophys Acta 2008; 1783:1718-27; PMID:18598724; http://dx.doi.org/10.1016/j.bbamcr.2008.06.001
46. Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, Ren J, Jin YH, Wang QJ, Gu XJ, Bi ZG, et al. C6-ceramide synergistically potentiates the anti-tumor effects of his-tone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis 2011; 2:e117; PMID:21368888; http://dx.doi.org/10.1038/cddis.2010.96
47. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009; 9:237-49; PMID:19275762; http://dx.doi. org/10.2174/156800909787580999
48. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 2010; 5:108; PMID:21080918; http://dx.doi. org/10.1186/1748-717X-5-108
49. Pandey AV, Mellon SH, Miller WL. Protein phospha-tase 2A and phosphoprotein SET regulate androgen production by P450c17. J Biol Chem 2003; 278:2837-44; PMID:12444089; http://dx.doi.org/10.1074/jbc. M209527200 (Pubitemid 36801187)
50. Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 2013; 13:51-65; PMID:23235911; http://dx.doi.org/10.1038/nrc3398
51. Morad SA, Levin JC, Shanmugavelandy SS, Kester M, Fabrias G, Bedia C, Cabot MC. Ceramide-antiestrogen nanoliposomal combinations-novel impact of hormonal therapy in hormone-insensitive breast cancer. Mol Cancer Ther 2012; 11:2352-61; PMID:22962326; http://dx.doi.org/10.1158/1535-7163.MCT-12-0594
52. Stover TC, Sharma A, Robertson G P, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005; 11:3465-74; PMID:15867249; http://dx.doi.org/10.1158/1078-0432.CCR-04-1770 (Pubitemid 40627901)
53. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphin-golipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006; 39:82-91; PMID:16828308; http://dx.doi.org/10.1016/j. ymeth.2006.05.004 (Pubitemid 44107706)